Zhang Xin, Luo Bing, Sun Minjie, Gao Deyu, Xu Sufang
Department of Medical Laboratory Center, Anhui No. 2 Provincial People's Hospital, Hefei, Anhui 230041, China.
Department of Medical Laboratory Center, Anhui No. 2 Provincial People's Hospital, Hefei, Anhui 230041, China.
Int Immunopharmacol. 2025 Apr 16;152:114426. doi: 10.1016/j.intimp.2025.114426. Epub 2025 Mar 9.
Thyroid cancer is the most prevalent endocrine malignancy, and its timely and accurate diagnostic and prognostic assessments are crucial for enhancing patient survival rates. As an important epigenetic modification, DNA methylation plays a key role in the regulation of gene expression and tumorigenesis. Recent studies increasingly indicate that abnormal DNA methylation patterns are closely associated with the onset and progression of thyroid cancer. This review discusses the role of DNA methylation in diagnosing thyroid adenocarcinoma, its impact on prognosis, and its potential utility in cancer immunotherapy. Additionally, it explores the prospect of using DNA methylation as a biomarker and highlights its significant potential in the personalized treatment of thyroid cancer. This article aims to serve as a resource for future research and clinical applications to advance the diagnosis and treatment of thyroid cancer.
甲状腺癌是最常见的内分泌恶性肿瘤,其及时准确的诊断和预后评估对于提高患者生存率至关重要。作为一种重要的表观遗传修饰,DNA甲基化在基因表达调控和肿瘤发生中起关键作用。最近的研究越来越表明,异常的DNA甲基化模式与甲状腺癌的发生和进展密切相关。本文综述了DNA甲基化在甲状腺腺癌诊断中的作用、其对预后的影响以及在癌症免疫治疗中的潜在应用。此外,还探讨了将DNA甲基化用作生物标志物的前景,并强调了其在甲状腺癌个性化治疗中的巨大潜力。本文旨在为未来的研究和临床应用提供参考,以推动甲状腺癌的诊断和治疗。